FATE
NASDAQFate Therapeutics Inc.
News · 26 weeks48+8%
2025-12-072026-05-31
Mix3090d
- Other18(60%)
- Insider7(23%)
- SEC Filings4(13%)
- Analyst1(3%)
Latest news
25 items- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees
- PRFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual MeetingFT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique ability to traffic to tumor site and functionally persist without the reliance on conditioning chemotherapy in allogeneic patient setting SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, presented clinical data this weeken
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- INSIDEROfficer Tahl Cindy sold $48,084 worth of shares (25,590 units at $1.88), decreasing direct ownership by 4% to 628,155 units (SEC Form 4) (withholding obligation)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERPresident and CEO Valamehr Bahram sold $54,482 worth of shares (28,946 units at $1.88), decreasing direct ownership by 4% to 635,762 units (SEC Form 4) to satisfy withholding tax4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- PRFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesSAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026. Presentation details are as follows: ASCO – American Society of Cancer Oncology Product Candidate: FT836 Title: Prelim
- PRCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
- ANALYSTJefferies resumed coverage on Fate TherapeuticsJefferies resumed coverage of Fate Therapeutics with a rating of Buy
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECSEC Form 10-Q filed by Fate Therapeutics Inc.10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
- SECFate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesRECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines Clinical data presented at Pediatric Rheumatology Symposium 2026 and Congress of Clinical Rheumatology – East 2026 highlights safety and efficacy of single dose of FT819 with reduced conditioning in SLE Preclinical data presented at the American Association for Cancer Research
- PRFate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual MeetingSingle dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; data shows broad and selective depletion of pathogenic immune cell subtypes in rheumatoid arthritis and systemic lupus erythematosus disease without the use of conditioning chemotherapy Preclinical data for FT836 shows effective elimination of broad
- INSIDEROfficer Tahl Cindy exercised 166,664 shares at a strike of $1.25, increasing direct ownership by 34% to 653,745 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERDirector Epstein Robert S exercised 25,000 shares at a strike of $1.69, increasing direct ownership by 221% to 36,331 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERDirector Rastetter William H exercised 25,000 shares at a strike of $1.69, increasing direct ownership by 221% to 36,331 units (SEC Form 4)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- PRFate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation provide opportunity for expedited regulatory pathway and advancement of FT819 Phase 2 potentially registrational clinical trial in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pi
- PRFate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836, will be featured at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026. Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, wher
- PRFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into
- PRFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 MeetingSAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be featured at the Congress of Clinical Rheumatology – East meeting, being held in Destin, FL on April 30 - May 3, 2026. The Company is participating in a Poster Rounding Session and will present an encore of its clinical data from the systemic lupus erythematosus (SLE) study arm of its o
- SECSEC Form DEFA14A filed by Fate Therapeutics Inc.DEFA14A - FATE THERAPEUTICS INC (0001434316) (Filer)
- SECSEC Form DEF 14A filed by Fate Therapeutics Inc.DEF 14A - FATE THERAPEUTICS INC (0001434316) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Redmile Group, Llc4/A - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Redmile Group, Llc4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
FATE FAQ
7 questionsWhat does Fate Therapeutics Inc. do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid...Where does FATE stock trade?
Fate Therapeutics Inc. (FATE) is listed on NASDAQ.What sector and industry is FATE in?
Fate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Fate Therapeutics Inc. go public?
Fate Therapeutics Inc. (FATE) completed its IPO in 2013.What are analysts saying about FATE?
Fate Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-05-19. Recent price targets range from $500.00 to $700.00.What companies are similar to FATE?
Notable peers in the same industry include TGTX (TG Therapeutics Inc.), TPTX (Turning Point Therapeutics Inc.), PSTX (Poseida Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare FATE side-by-side with any of them on Quantisnow.How can I track FATE on Quantisnow?
Quantisnow aggregates Fate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FATE to receive live email and push alerts on every new disclosure.